FDA will take the first pharmaceutical therapy for short bowel syndrome – NPS Pharmaceuticals Inc.’s Gattex (teduglutide) – to an Oct. 16 Gastrointestinal Drugs Advisory Committee where panel members will balance mixed results from an initial study with positive findings from a confirmatory trial.
Teduglutide, which has orphan drug status, has had a long road to regulatory review. FDA requested the second study in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?